Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05876715 · ClinicalTrials.gov registry record · Phase 1
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
A Phase 1 study of Advanced Soft Tissue Sarcoma, sponsored by Erlinda M Gordon.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05876715 is a Phase 1 study of Advanced Soft Tissue Sarcoma that is actively recruiting participants, run by Erlinda M Gordon. The registered enrollment target is 40 participants, below the 85-participant average among 6 other Advanced Soft Tissue Sarcoma trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05876715, a Phase 1 study of Advanced Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Erlinda M Gordon.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
Conditions Studied
Interventions
- DRUG Lurbinectedin
Study Locations (1)
California
- Sarcoma Oncology Research Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05876715
The ClinicalTrials.gov registry entry for NCT05876715 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 6 other Advanced Soft Tissue Sarcoma trials with a reported enrollment target (53% lower). The listed sponsor is Erlinda M Gordon, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Lurbinectedin is the first listed.
NCT05876715 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05876715 about?
NCT05876715 is a clinical study titled "LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma". This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
What is the current status of trial NCT05876715?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-06-07. Estimated completion is 2026-09-30.
What conditions does trial NCT05876715 study?
This clinical trial studies the following conditions: Advanced Soft Tissue Sarcoma.
What interventions are being tested in trial NCT05876715?
The interventions under investigation include: Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05876715?
This trial is sponsored by Erlinda M Gordon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05876715 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Actinium Therapy for Late-stage Aggressive Sarcomas
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Lurbinectedin + Doxorubicin In Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
RECRUITING · Phase 2
-
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.